Mostrando 4 resultados de: 4
Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
ArticleAbstract: Background: Progress in immunotherapy has revolutionized the treatment landscape for advanced lung cPalabras claves:immunotherapy, long-term survival, non–small cell lung cancer, survival mixture modelsAutores:Alfonso S., Carmen Elena Viada, Lage Davila A., Luaces P.L.o., Muchene L., Neninger Vinageras E., Rodríguez P.C., Sánchez L., Shkedy Z., Tania CrombetFuentes:scopusIdentifying pbkp_redictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients
ArticleAbstract: Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately asPalabras claves:Causal inference, CIMAvaxEGF, Non-small-cell lung cancer, Pbkp_redictive biomarkersAutores:Alonso A., Lage Davila A., Luaces P.L.o., Molenberghs G., Saavedra Hernández D., Sánchez L., Tania Crombet, Van der Elst W.Fuentes:scopusIs there a subgroup of long-term evolution among patients with advanced lung cancer?: Hints from the analysis of survival curves from cancer registry data
ArticleAbstract: Background: Recently, with the access of low toxicity biological and targeted therapies, evidence ofPalabras claves:Long-term survivors, Mixture models, Non-small-cell lung cancer, SurvivalAutores:Ballesteros J., Carmen Elena Viada, Galán Y.H., Lage Davila A., Luaces P.L.o., Sánchez L., Tania CrombetFuentes:scopusSuperior efficacy and safety of a nonemulsive variant of the NGcGM3/VSSP vaccine in advanced breast cancer patients
ArticleAbstract: NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vacPalabras claves:Breast Cancer, NGcGM3/VSSP vaccine, SurvivalAutores:Arencibia M., Cabrera L., Carmen Elena Viada, Cepeda M., De La Torre A.V., Domecq M., Durán Y., Durrutí D., Fernandez L.E., Hernández J.J., Hernández L., Mabel Álvarez, Moreno Y.G., Pérez K., Ruiz R., Sánchez J.L., Sánchez L., Santiesteban E.R., Valls A.R., Vega A.M.Fuentes:scopus